A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Inclusion Criteria:

- Subjects from 16 to 75 years, both inclusive

- Well-characterized focal epilepsy or epileptic syndrome

- Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not
secondarily generalized per 4 weeks during the 8-week Baseline Period

- Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic
Drugs (AEDs) with the second AED ≤ 50% of the minimum recommended maintenance dose

Exclusion Criteria:

- Seizure type IA non-motor as only seizure type

- History or presence of seizures occurring too frequently or indistinctly separated to
be reliably counted during the 6 months preceding Visit 1 or during Baseline

- Other serious uncontrolled disease